News

Video

Datopotamab Deruxtecan (Dato-DXd) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) – Nonsquamous (NSQ) Histology in the Phase 3 TROPION-Lung01 Trial

Author(s):

Jacob Sands, MD

Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented at the 2024 European Lung Cancer Congress (ELCC).

Related Videos
Alec Watson, MD
Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States
DB-12
5-Year Follow-Up of Cohort 1 from the SEQUOIA Study
RMC-9805
LGSOC 2024
Balazs Halmos, MD
Balazs Halmos, MD
Suresh Senan, MRCP, FRCR, PhD, full professor, treatment and quality of life, full professor, cancer biology and immunology, full professor, radiation oncology, professor, clinical experimental radiotherapy, Amsterdam University Medical Centers
Related Content
Lung Cancer | stock.adobe.com
December 20th 2024

China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

FDA
December 18th 2024

FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

FDA
December 17th 2024

FDA Issues Complete Response Letter to Subcutaneous Amivantamab BLA in EGFR+ NSCLC

NRG1 Fusions in Lung Cancer | Image Credit: © catalin – stock.adobe.com
December 17th 2024

NRG1 Fusions Emerge as New Target of Interest in Lung, Pancreatic Cancers